Evaluation of the Pharmacokinetics of Ulimorelin in Subjects With Hepatic Impairment and Healthy Subjects

Digestive System Disorders Clinical Trial

Official title:
Evaluation of the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ulimorelin in Subjects With Mild, Moderate and Severe Hepatic Impairment, in Comparison With Healthy Subjects

Status Completed

Clinical Trial Summary

Evaluation of the effect of hepatic impairment on the pharmacokinetics of ulimorelin after a single intravenous (IV) dose in order to identify potential patients at risks in terms of severity of hepatic dysfunction and to determine whether their dosage should be adjusted.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01405599
Study type	Interventional
Source	Norgine
Contact
Status	Completed
Phase	Phase 1
Start date	June 2011
Completion date	October 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01770808` - A Study to Determine if Aquamin (as AquaCal and AquaPT) Improves Digestive Discomfort	N/A
Completed	`NCT01405612` - Study to Examine the Effect of Ulimorelin on the Pharmacokinetics of Midazolam in Healthy Volunteers	Phase 1
Unknown status	`NCT01318928` - The Treatment of Periodontal Diseases	Phase 4
Completed	`NCT01304394` - Safety During Use of Paediatric Triple Chamber Bag Formulas	Phase 3
Completed	`NCT01485328` - Protocol: Phytomedicine-AMARGOL®, Clinical Trial for Efficacy Proof on Therapeutics	Phase 3